Clinical Trial: A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686445) titled 'A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression' on June 23.

Brief Summary: The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5 protein. RAS genes help control how cells grow and divide. Mutations in RAS can cause cells to grow uncontrollably and contribute to cancer. CEACAM5 is a protein found on the surface of some cancer cells and may serve as a target for AN4035. This is the first time AN4035 is being tested in humans. The ...